Source: Annual Congress 2002 - Aspects of respiratory disease in primary care
Disease area: Airway diseases

Abstract

This study was designed to describe the medical costs incurred by persons with COPD in France in 2001 according to the severity of the disease. A retrospective and prospective cost of illness survey of patients enrolled by a stratified sample of general practitioners and chest physicians was implemented on a one year period. All direct costs were computed from the healthcare's viewpoint, distinguishing between costs associated with COPD regular treatment, exacerbations, other COPD complications and other medical consumption. Among the 255 patients included 56% had a moderate COPD (80%>FEV1>50%), 27% a moderately severe one (50%>= FEV1>35%) and 17% a severe one (FEV1[lte] 35%). Moderate COPD had the lowest cost (€3,697 per patient per year), severe COPD had the highest cost (€7,502), and moderately severe COPD had an intermediate cost (€3,813). The main costs drivers were hospitalizations and inpatient physician services (35% of total costs) and prescription medications (31%). 41% of the total costs were related to usual COPD treatment and 25% to COPD complications including exacerbations. 77% of patients experimented at least one acute exacerbation (average number : 1.7 episodes, SD : 3.0). The burden of COPD is considerable in France and results suggest a relation with FEV1 levels.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Fournier, P. Godard, B. Housset, G. Huchon, I. Durand-Zaleski, B. Detournay, Groupe SCOPE* (Paris, Montpellier, Creteil, Bourg-La-Reine, France). Costs associated with COPD in France : the SCOPE study. Eur Respir J 2002; 20: Suppl. 38, 2979

Member's Comments

No comment yet.

Related content which might interest you: The ICE prospective study: Italian Costs for Exacerbations in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 517s Year: 2005 Risk of cardiovascular events following COPD hospitalisation: Findings from the China Kadoorie Biobank cohort study Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 The economic burden of COPD in a Swedish cohort: The ARCTIC study Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care Year: 2016 ICS and risk of pneumonia in Swedish COPD patients: The ARCTIC study Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 Statins and mortality in COPD in the COMIC study: A prospective COPD cohort study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Comorbidities in Swedish COPD and non-COPD patients: ARCTIC study Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016 Predictors of long-term mortality after hospitalization for COPD; A Scandinavian multicentre study Source: International Congress 2014 – Longitudinal studies of respiratory disease Year: 2014 The ICE study, Italian costs for exacerbations in COPD: a project of the Italian Association for COPD Source: Annual Congress 2003 - Outcome of acute exacerbations in COPD Year: 2003 Costs and effects of structured COPD care – An observational, matched-cohort study Source: Annual Congress 2013 –Early diagnosis and effectiveness of disease management in primary care Year: 2013 COPD-specific co-morbidity test (COTE) for predicting mortality in COPD – Results of an European, multicenter study Source: International Congress 2014 – Markers Year: 2014 Clinical and economic factors associated with spirometry-diagnosed COPD in the Swedish ARCTIC study Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care Year: 2016 Effect of COPD medications on exacerbation rates in a real-life COPD patient cohort - data from the Czech Multicenter Research Database of COPD. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study Source: ERJ Open Res, 7 (3) 00004-2021; 10.1183/23120541.00004-2021 Year: 2021 Long-term survivalaccording to Czech clinical phenotypes of COPD- Czech multicentre research database of severe COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Diagnosing asthma and COPD in primary care patients in Serbia: A multicenter study Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care Year: 2012 Patient-reported outcomes as predictors of COPD exacerbations - a prospective study Source: International Congress 2014 – COPD markers Year: 2014 The prevalence of asthma and COPD in Italy: A practice-based study Source: Annual Congress 2010 - Prevalence and incidence of asthma and COPD Year: 2010 Health resource utilisation due to IPF exacerbations in Spain: prospective, observational, multicentric study (OASIS study) Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Factors related to discontinuous use of inhaled drugs in COPD patients: A population-based cohort study in Lazio (Italy) Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD Year: 2012 An Italian, observational, multicenter trial to describe the therapeutic approach according to COPD GOLD guidelines during three years of observation: The MISTRAL study Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014